SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapies for metabolic and endocrine disorders. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.

Viking Therapeutics Inc

Viking Therapeutics is trending following its recent announcement to advance its oral obesity drug directly to Phase 3 with FDA validation, significantly accelerating its timeline within the rapidly expanding GLP-1 market. Community discussion reflects strong conviction in the company's undervalued pipeline and potential for a strategic partnership or acquisition, further bolstered by recent regulatory action against compounded alternatives.

HubSpot, Inc. engages in cloud-based customer relationship management. Its platform includes marketing, sales, service, operations and content management system, as well as other tools, integrations and native payment solutions. It operates through the following geographical segments: Americas, Europe and Asia Pacific. The company was founded by Brian Patrick Halligan and Dharmesh Shah on April 4, 2005, and is headquartered in Cambridge, MA.

HubSpot Inc

HubSpot ($HUBS) is trending after its latest financial results, which, despite exceeding expectations and including a significant share repurchase program, led to a sharp stock decline. This has ignited intense community debate, with many bulls arguing the stock is deeply oversold and fundamentals are strong, while bears double down on the "Death By AI" narrative, fearing broad AI disruption for the SaaS sector.

Fastly, Inc. provides real-time content delivery network services. It offers edge compute, edge delivery, edge security, edge applications like load balancing and image optimization, video on demand, and managed edge delivery. The company was founded by Artur Bergman, Tyler McMullen, Simon Wistow, and Gil Penchina in March 2011 and is headquartered in San Francisco, CA.

Fastly Inc - Ordinary Shares - Class A

Fastly Inc

Fastly is trending after its latest earnings report showed record revenue, gross margin, and a return to profitability, prompting excitement about a potential turnaround. The community is actively discussing the company's strong security growth and the increasing tailwinds from AI adoption, with many anticipating further upside for the edge computing provider.

NovoCure Ltd. is an oncology company which engages in the development, manufacture, and commercialization of Optune for the treatment of a variety of solid tumors. Its platform is called the Tumor Treating Field which uses electric fields tuned to specific frequencies to disrupt solid tumor cancer cell division. The company was founded by Yoram Palti in 2000 and is headquartered in St. Helier, Jersey.

NovoCure Ltd

NovoCure is trending after its Optune Pax therapy received FDA approval for locally advanced pancreatic cancer, marking the first new treatment in nearly three decades; however, community sentiment is split between enthusiasm for this breakthrough and skepticism regarding the modest survival extension.

QuantumScape Corp. engages in developing next-generation solid-state lithium-metal batteries. The company’s next-generation batteries are designed to enable greater energy density, faster charging, and enhanced safety to support the transition away from legacy energy sources toward a lower-carbon future. The company was founded by Jagdeep Singh, Tim Holme, and Fritz B. Prinz in May 2010 and is headquartered in San Jose, CA.

QuantumScape Corp - Ordinary Shares - Class A

QuantumScape Corp

QuantumScape is at the forefront of community discussion after initiating its Eagle Line pilot production and shipping B-samples to multiple automotive OEMs, intensifying speculation around upcoming commercialization timelines and potential partnerships for its groundbreaking solid-state battery technology.

Beta Technologies, Inc. engages in the designing, manufacturing and sell electric aircraft, electric propulsion systems, charging systems and components. It focuses on the enabling technologies essential to electric aviation, including batteries, motors, flight control systems and a nationwide network of electric charging and related equipment. The company was founded by Kyle B. Clark in 2017 and is headquartered in South Burlington, VT.

BETA Technologies Inc - Ordinary Shares - Class A

BETA Technologies is seeing heightened interest after a major e-commerce company disclosed a significant stake, alongside multiple analyst upgrades citing upcoming certification milestones and strategic partnerships. The community is actively debating the company's potential in the evolving eVTOL market, comparing its trajectory against industry peers.

Oxford Lane Capital Corp. is a closed-end management investment company, which engages in investing in debt and equity tranches of collateralized loan obligation vehicles. The company was founded on June 9, 2010 and is headquartered in Greenwich, CT.

Oxford Lane Capital Corp

Oxford Lane Capital Corp is trending due to a steep stock price decline and a substantial dividend cut, which is generating widespread investor frustration and debate within the community over management's strategy and the fund's long-term stability amidst a challenging CLO market.

Churchill Capital Corp. X is a blank check company, which was created for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company was founded by Michael Klein on January 4, 2024 and is headquartered in New York, NY.

Churchill Capital Corp X - Ordinary Shares - Class A

Churchill Capital Corp X 

Churchill Capital Corp X (CCCX) is trending with its imminent merger into quantum technology leader Infleqtion, driven by recent NASA and DOE contracts, validating its technology. The community is actively discussing its significant undervaluation compared to sector peers and anticipating its debut on the NYSE as INFQ, with many seeing current price action as a prime buying opportunity.

Monad is a high-performance Layer 1 blockchain that processes 10,000 transactions per second with near-zero fees. The platform delivers high performance without compromising on security or decentralization, creating the infrastructure needed for complex applications that require high-frequency activity.  One of Monad’s key innovations lies in how it handles transaction processing. Instead of processing transactions one at a time like traditional blockchains, Monad processes multiple transactions simultaneously through parallel execution.   The system separates the agreement process from the execution process, allowing validators to first agree on which transactions to include and in what order, then having more time to execute those transactions without slowing down consensus. This approach, combined with a custom-built database called MonadDB, dramatically increases throughput while maintaining accuracy.  Monad also offers complete EVM compatibility, where applications built for Ethereum work on Monad without any code modifications, and users can connect with familiar wallets like MetaMask just as they would on Ethereum. Developers can immediately tap into Ethereum's established ecosystem of tools, libraries, and applications while benefitting from Monad’s performance improvements. The platform also runs on consumer-grade hardware rather than expensive specialized equipment, making it accessible for more people to participate in securing the network.  Monad has raised approximately 244 million dollars in total funding across multiple rounds. The company secured 19 million dollars in a seed round in February 2023 led by Dragonfly Capital, followed by a 225 million dollar Series A round in April 2024 led by Paradigm at a 3 billion dollar valuation. Other notable investors include Electric Capital, Greenoaks, Coinbase Ventures, and prominent angel investors such as Naval Ravikant.

Monad

Monad (MON) is actively debated following its recent launch, with the community highlighting its advanced EVM-compatible Level 1 blockchain, promising integrations, and attractive staking yields as catalysts for long-term growth. However, others express caution over its tokenomics and potential for future supply dilution, despite its robust technology and recent performance during broader crypto market volatility.

GitLab, Inc. engages in the intelligent DevSecOps platform for software innovation. The firm enables organizations to increase developer productivity, improve operational efficiency, reduce security and compliance risk, and accelerate digital transformation. The company was founded by Dmitriy Zaporozhets and Sid Sijbrandij in 2011 and is headquartered in San Francisco, CA.

Gitlab Inc - Ordinary Shares - Class A

Gitlab Inc

GitLab is trending as its stock recently plunged following a mixed earnings report that, despite a top and bottom-line beat, included conservative guidance and a net loss, triggering multiple analyst downgrades. The community is sharply divided between those calling the stock a 'buy the dip' candidate with strong buyout potential, particularly from Datadog, and others citing persistent losses and competitive pressure as reasons for its decline.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Biotech Stocks To Add to Your Watchlist - February 11th

Moderna, Danaher, Vertex Pharmaceuticals, Medpace, and Upstream Bio are the five Biotech stocks to watch today, according to MarketBeat's stock screener tool. Biotech stocks are shares of companies...

Wealthfront Advisers LLC Trims Position in Vertex Pharmaceuticals Incorporated $VRTX

Wealthfront Advisers LLC lessened its holdings in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX - Free Report) by 14.9% in the third quarter, according to the company in its most recent...

LLY Expands Cell Therapy Ambitions With $2.4B Orna Therapeutics Deal

Eli Lilly is set to buy Orna Therapeutics for $2.4B to expand in vivo CAR-T and circular RNA capabilities, signaling a long-term push to diversify its pipeline.

Vertex Gears Up to Report Q4 Earnings: Is a Beat in the Cards?

VRTX is set to report Q4 results amid strong Trikafta demand. Alyftrek launches are gaining traction while investors are eyeing Casgevy and Journavx sales.

Oppenheimer Asset Management Inc. Grows Stock Holdings in Vertex Pharmaceuticals Incorporated $VRTX

Oppenheimer Asset Management Inc. increased its stake in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX - Free Report) by 18.5% during the 3rd quarter, according to its most recent filing...

Should You Buy Vertex Pharmaceuticals Before Feb. 12?

Key PointsVertex's core franchise probably won't lead to any surprises, but newer launches could...

Top Biotech Stocks To Add to Your Watchlist - February 9th

argenex, Vertex Pharmaceuticals, Danaher, Moderna, and Medpace are the five Biotech stocks to watch today, according to MarketBeat's stock screener tool. Biotech stocks are shares of publicly traded...

Will These 5 Drug Bigwigs Surpass Q4 Earnings Forecasts?

Let's look at five pharma and biotech companies, AZN, INCY, GILD, VRTX and MRNA, which are scheduled to release their fourth-quarter 2025 results this week.

Seeking Clues to Vertex (VRTX) Q4 Earnings? A Peek Into Wall Street Projections for Key Metrics

Evaluate the expected performance of Vertex (VRTX) for the quarter ended December 2025, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.

How to Find Strong Medical Stocks Slated for Positive Earnings Surprises

Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.

Vertex Pharmaceuticals, Inc. is a global biotechnology company, which engages in the business of discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases. The firm focuses on development and commercializing therapies for the treatment of cystic fibrosis, infectious diseases including viral infections such as influenza and bacterial infections, autoimmune diseases such as rheumatoid arthritis, cancer, inflammatory bowel disease and neurological disorders including pain and multiple sclerosis. The company was founded by Joshua S. Boger in 1989 and is headquartered in Boston, MA.

Vertex Pharmaceuticals, Inc.

Beat EPS and revenue

Beat EPS, miss revenue

Miss EPS, beat revenue

Miss EPS and revenue

What do you expect from $COIN earnings on Thursday?

Fiscal Period	Estimated	Reported	Surprise	Result
Q4 '25	$5.11	--	--	N/A
Q3 '25	$4.58	$4.80	4.91%	BEAT
Q2 '25	$4.27	$4.52	5.80%	BEAT
Q1 '25	$4.25	$4.06	-4.37%	MISSED
Q4 '24	$4.02	$3.98	-0.90%	MISSED

VRTX
Vertex Pharmaceuticals, Inc.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q4 '25

Historical Earnings

Latest VRTX News

VRTXVertex Pharmaceuticals, Inc.